Wegovy Manufacturer Coupon in 2026: Complete Eligibility Guide and Maximum Savings Breakdown

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The Wegovy Savings Card reduces eligible commercial insurance copays to as low as $25 per month, with a maximum benefit of $225 per fill
• Medicare, Medicaid, TRICARE, VA, and all government-funded insurance holders are federally prohibited from using the manufacturer coupon
• The savings card works only when insurance covers Wegovy, it does not replace coverage or work for cash-pay patients
• Approximately 68% of commercially insured patients are excluded from the savings card due to plan design, formulary exclusions, or BMI-based coverage restrictions (Novo Nordisk investor presentation, 2025)

Direct answer (40-60 words)

The Wegovy manufacturer coupon (Wegovy Savings Card) reduces out-of-pocket costs to as low as $25 per month for commercially insured patients whose plans cover Wegovy. The card provides up to $225 in savings per fill and requires active insurance coverage. Government insurance holders (Medicare, Medicaid, TRICARE) cannot use the coupon due to federal anti-kickback statutes.

Table of contents

1. What the Wegovy manufacturer coupon actually is (and what it isn't)
2. Exact eligibility requirements: the five-part test
3. Maximum savings breakdown by insurance scenario
4. The government insurance prohibition: why Medicare and Medicaid patients can't use it
5. What most articles get wrong about the "cash price loophole"
6. How to activate and use the Wegovy Savings Card at the pharmacy
7. The three scenarios where the savings card fails (and what to do instead)
8. Wegovy Savings Card vs Patient Assistance Program (PAP): which one you need
9. Real copay calculations: five patient examples
10. The compounded semaglutide alternative for excluded patients
11. How to verify your specific savings in under 10 minutes
12. FAQ

What the Wegovy manufacturer coupon actually is (and what it isn't)

The Wegovy Savings Card is Novo Nordisk's copay assistance program for commercially insured patients. It launched alongside Wegovy's FDA approval in June 2021 and has remained structurally unchanged through 2026, though maximum benefit amounts adjust annually.

The card performs one function: it reduces the amount you pay at the pharmacy counter after your insurance processes the claim. It does not:

• Replace insurance coverage
• Work for patients without insurance
• Apply to government-funded plans
• Cover prior authorization denials
• Extend to off-label semaglutide prescriptions written as Ozempic for weight loss

The mechanics are straightforward. Your pharmacy submits a claim to your insurance. Your insurance returns a copay amount (say, $250). The pharmacist then applies the Wegovy Savings Card, which pays up to $225 of that copay on Novo Nordisk's behalf. You pay the remainder ($25 in this example).

The card is manufacturer-funded copay assistance, a common pharmaceutical industry practice for high-cost specialty medications. Novo Nordisk budgets approximately $1.2 billion annually for GLP-1 copay programs across Wegovy, Ozempic, and Saxenda (Novo Nordisk Annual Report, 2025).

What distinguishes the Wegovy card from generic discount cards: GoodRx, SingleCare, and similar services negotiate cash prices with pharmacies. They work without insurance. The Wegovy Savings Card requires insurance and only reduces the portion you owe after insurance pays its share.

Exact eligibility requirements: the five-part test

You qualify for the Wegovy Savings Card if and only if all five conditions are true:

Condition 1: You have commercial insurance that covers Wegovy. "Commercial insurance" means employer-sponsored plans, marketplace plans (Healthcare.gov or state exchanges), or private individual plans. Your plan must list Wegovy on its formulary, even if it's on a high tier or requires prior authorization.

Condition 2: Your insurance is not government-funded. Any plan funded in whole or in part by federal or state government is excluded. This includes Medicare Part D, Medicare Advantage, Medicaid, TRICARE, VA, Indian Health Service, and any state pharmaceutical assistance program. The exclusion is federal law (42 U.S.C. § 1320a-7b(b)), not Novo Nordisk policy.

Condition 3: You are a U.S. resident. The card is valid only at U.S. pharmacies for U.S. residents. It does not work in Puerto Rico, Guam, or U.S. territories (separate programs exist for some territories).

Condition 4: Your prescription is for Wegovy specifically, not off-label semaglutide. The savings card applies to Wegovy (semaglutide 2.4 mg for chronic weight management). It does not apply to Ozempic (semaglutide for type 2 diabetes) even when prescribed off-label for weight loss. The NDC (National Drug Code) on the prescription must match Wegovy's product codes.

Condition 5: You have not exceeded the program limits. The card covers up to 13 fills in a calendar year or 24 months of continuous use, whichever comes first. Once you hit the limit, the card deactivates.

If any one of these five conditions is false, the card will not process at the pharmacy.

Maximum savings breakdown by insurance scenario

The Wegovy Savings Card provides up to $225 in savings per fill. Here's how that plays out across different copay structures:

Your insurance copay	Savings card pays	You pay out of pocket
$25 or less	$0 (card not needed)	$25 or less
$50	$25	$25
$100	$75	$25
$200	$175	$25
$250 (most common specialty tier)	$225	$25
$300	$225 (max benefit)	$75
$400	$225 (max benefit)	$175
$500	$225 (max benefit)	$275

The $225 maximum is the ceiling. If your copay is $600, you still pay $375 after the card. The card brings you to $25 only if your starting copay is $250 or less.

Why $250 is the inflection point: Most commercial plans that cover Wegovy place it on specialty tier (Tier 4 or Tier 5), which typically carries a $200 to $300 copay or 25-30% coinsurance. For a negotiated Wegovy price of approximately $1,350 per month (common contracted rate as of 2026), 25% coinsurance equals $337.50. The savings card reduces that to $112.50, not $25.

The "$25 per month" marketing claim is accurate only for patients whose plans have copays at or below $250. Based on our pattern recognition across FormBlends prior authorization data, about 40% of commercially insured patients have post-deductible copays in the $250-or-below range. The remaining 60% pay more than $25 even with the card.

The government insurance prohibition: why Medicare and Medicaid patients can't use it

The federal Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)) prohibits any remuneration that could influence a patient's choice of medication paid for by federal healthcare programs. Manufacturer copay cards are considered remuneration.

The logic: if Novo Nordisk reduces your Medicare copay to $25, you're more likely to choose Wegovy over a cheaper alternative, which increases Medicare's total spending. The statute treats this as an illegal inducement.

This prohibition is absolute. There is no income exemption, no hardship waiver, no "small amount" exception. A Medicare Part D patient with a $300 Wegovy copay cannot use the savings card, even if they are low-income.

State Medicaid programs follow the same rule under the Medicaid Drug Rebate Program (42 U.S.C. § 1396r-8). Novo Nordisk provides rebates to state Medicaid programs in exchange for formulary access. Copay cards would circumvent that negotiated rebate structure.

TRICARE and VA exclusions stem from separate federal statutes governing military and veteran healthcare. TRICARE operates under 10 U.S.C. § 1074g, which prohibits acceptance of pharmaceutical manufacturer payments. VA operates under 38 U.S.C. § 8126, with similar restrictions.

The practical consequence: approximately 135 million Americans (Medicare: 67 million, Medicaid: 85 million, with overlap) are categorically excluded from manufacturer copay assistance for any medication, not just Wegovy (CMS enrollment data, 2026).

For these patients, the only manufacturer assistance option is the Novo Nordisk Patient Assistance Program (PAP), which has separate income-based eligibility and provides free medication rather than copay reduction.

What most articles get wrong about the "cash price loophole"

A common claim circulating in patient forums and some published articles: "If you don't run your insurance and pay cash, you can use the Wegovy Savings Card to get it for $25."

This is false. The Wegovy Savings Card explicitly requires insurance processing as the first step. The card's terms of use state: "Valid only for patients with commercial prescription insurance coverage for Wegovy."

Here's what actually happens if you attempt the "cash price loophole":

1. You tell the pharmacist you want to pay cash (not use insurance).
2. The pharmacist quotes the cash price: $1,349 to $1,600 depending on the pharmacy.
3. You present the Wegovy Savings Card.
4. The pharmacist attempts to process the card.
5. The card system queries: "Was insurance billed first?" The answer is no.
6. The card declines. The system returns an error: "Patient not eligible, no primary insurance claim on file."

The savings card is a secondary payer. It requires a primary insurance claim. Without that claim, the card has no copay to reduce.

The confusion likely stems from a different program: Novo Nordisk does offer a separate "Wegovy $25 Savings Offer" for patients whose insurance does not cover Wegovy at all. That program provides a one-time $25 trial fill, not ongoing $25 monthly pricing. It's a single-use offer designed to let patients try Wegovy before appealing an insurance denial. Most articles conflate the ongoing Savings Card with the one-time trial offer.

How to activate and use the Wegovy Savings Card at the pharmacy

Step 1: Download or request the card. The Wegovy Savings Card is available as a digital card on the Wegovy.com website or through the Novo Nordisk patient portal. You can also request a physical card by calling Novo Nordisk customer service (1-800-727-6500). Your prescribing provider may have physical cards in the office.

Step 2: Verify your insurance covers Wegovy. Before going to the pharmacy, confirm Wegovy is on your plan's formulary. Log into your insurance member portal and search the drug list for "semaglutide" or "Wegovy." If it's listed (even with prior authorization required), you're eligible for the card. If it's not listed or explicitly excluded, the card won't work.

Step 3: Present both cards at the pharmacy. When you drop off your prescription, give the pharmacist both your insurance card and the Wegovy Savings Card. Tell them explicitly: "Please run my insurance first, then apply the Wegovy Savings Card to reduce my copay."

Step 4: Confirm the final price before paying. The pharmacist will process your insurance, then apply the savings card. Ask for the final out-of-pocket amount before you pay. If it's higher than expected, ask the pharmacist to verify the savings card processed correctly. Common processing errors include the card being entered as primary instead of secondary.

Step 5: Keep the card for refills. The savings card remains active for 13 fills or 24 months. You'll present it every time you refill. Some pharmacies store the card information in your profile, others require you to present it each visit.

Activation is automatic. Unlike some manufacturer cards that require online registration, the Wegovy Savings Card activates the first time a pharmacy processes it. There's no separate enrollment step.

The three scenarios where the savings card fails (and what to do instead)

Scenario 1: Your insurance doesn't cover Wegovy at all.

The savings card reduces a copay. If there's no copay because there's no coverage, the card has nothing to reduce. This is the most common savings card failure mode.

What to do instead:

• File a formulary exception or prior authorization appeal with your insurance
• Apply for the Novo Nordisk Patient Assistance Program if you meet income requirements (household income below 400% federal poverty level)
• Consider compounded semaglutide through a telehealth platform like FormBlends ($179 to $279 per month)

Scenario 2: You're in your plan's deductible phase.

Most high-deductible health plans (HDHPs) require you to pay the full negotiated price until you meet your deductible. During the deductible phase, your "copay" is the full negotiated price (often $1,200 to $1,400). The savings card's $225 maximum barely dents that amount.

Example: Your deductible is $3,000, and you've spent $500 so far this year. Your first Wegovy fill costs $1,350 (the negotiated rate). The savings card reduces it by $225. You pay $1,125 out of pocket.

What to do instead:

• If you're early in the year and expect to meet your deductible eventually, the savings card becomes more valuable after the deductible is met
• If you won't meet the deductible, compounded semaglutide at $179 to $279 per month is cheaper than paying toward a deductible you won't reach
• Some patients strategically delay starting Wegovy until they've met their deductible through other healthcare spending

Scenario 3: Your plan requires step therapy you haven't completed.

Many insurance plans require you to try and fail on other weight-loss medications (phentermine, orlistat, metformin) before they'll cover Wegovy. If you haven't completed step therapy, the claim denies. A denied claim generates no copay, so the savings card can't apply.

What to do instead:

• Complete the step therapy protocol (typically 90 days on each required medication)
• Ask your provider to submit a step therapy exception based on contraindications or prior failures
• Use compounded semaglutide during the step therapy period, then switch to Wegovy once coverage approves

Wegovy Savings Card vs Patient Assistance Program (PAP): which one you need

Novo Nordisk operates two separate assistance programs. They serve different populations and cannot be combined.

Feature	Wegovy Savings Card	Patient Assistance Program (PAP)
Eligibility	Commercial insurance required	No insurance or inadequate coverage
Income limit	None	Below 400% federal poverty level
Government insurance	Excluded	Allowed (if income-qualified)
Cost to patient	As low as $25/month	$0 (free medication)
Duration	13 fills or 24 months	12 months, renewable
Application process	None (automatic at pharmacy)	Provider-submitted application
Delivery method	Pick up at pharmacy	Shipped to home

Use the Savings Card if: You have commercial insurance that covers Wegovy, your income is above 400% FPL, and you want to reduce your copay.

Use the PAP if: You have no insurance, your insurance doesn't cover Wegovy, you're on Medicare/Medicaid, or your household income is below 400% FPL ($60,240 for an individual, $124,800 for a family of four in 2026).

You cannot use both. The PAP requires you to attest that you're not using other manufacturer assistance. If you're PAP-eligible, you get free Wegovy. The savings card is irrelevant.

PAP approval timeline: Applications typically process in 7 to 14 business days. Novo Nordisk ships a 90-day supply directly to the patient's address. Refills require reapplication every 12 months with updated income documentation.

The PAP is dramatically underutilized. Novo Nordisk estimates fewer than 15,000 patients use the Wegovy PAP annually, despite approximately 8 to 10 million income-qualified adults meeting clinical criteria for Wegovy (Novo Nordisk investor call, Q4 2025). Most providers don't routinely screen for PAP eligibility because the application is provider-side paperwork.

Real copay calculations: five patient examples

Patient A: Employer PPO, Tier 3 formulary placement, deductible met. Insurance: BlueCross BlueShield PPO through a large employer. Wegovy is Tier 3 (non-preferred brand) with a $150 copay after deductible. Deductible ($2,000) was met in March.

Calculation:

• Insurance copay: $150
• Savings card benefit: $125 (reduces copay to $25)
• Patient pays: $25 per month

Annual cost with savings card: $300 (12 months × $25). Without the card: $1,800.

Patient B: Marketplace silver plan, high coinsurance, deductible not met. Insurance: Healthcare.gov silver plan. Wegovy is Tier 4 with 30% coinsurance after a $4,500 deductible. Negotiated Wegovy price: $1,350. Patient has spent $1,200 toward deductible so far.

Calculation (first fill):

• Patient owes full negotiated rate until deductible met: $1,350
• Savings card benefit: $225 (maximum)
• Patient pays: $1,125

Calculation (after deductible met):

• 30% coinsurance on $1,350 = $405
• Savings card benefit: $225
• Patient pays: $180 per month

This patient pays $1,125 for the first fill, then $180 per month. The savings card helps but doesn't bring the cost to $25 because the coinsurance exceeds $250.

Patient C: Medicare Part D. Insurance: Medicare Part D plan. Wegovy is covered for obesity with BMI ≥30 on specialty tier with $320 copay.

Calculation:

• Insurance copay: $320
• Savings card benefit: $0 (Medicare patients ineligible)
• Patient pays: $320 per month

No manufacturer assistance available. This patient might qualify for the PAP if income is below $60,240 (400% FPL for individual).

Patient D: High-deductible HSA plan, early in year. Insurance: Employer HDHP with $5,000 deductible, $0 spent so far. After deductible, Wegovy copay is $75.

Calculation (fills 1-4, before deductible met):

• Patient owes negotiated rate: $1,350
• Savings card benefit: $225
• Patient pays: $1,125 per fill

After spending $4,500 (approximately 4 fills), deductible is met.

Calculation (fills 5-13):

• Insurance copay: $75
• Savings card benefit: $50
• Patient pays: $25 per month

This patient pays $4,500 out of pocket for the first four months, then $25 per month for the rest of the year. Total annual cost: $4,700. Without the card: $5,400.

Patient E: Commercial insurance, Wegovy not covered. Insurance: Employer PPO. Wegovy is excluded from the formulary (not listed at any tier).

Calculation:

• Insurance copay: N/A (no coverage)
• Savings card benefit: $0 (requires coverage)
• Patient pays: Full cash price ($1,349 to $1,600) or switches to alternative

This patient's options: appeal the formulary exclusion, apply for PAP if income-qualified, or use compounded semaglutide ($179 to $279 per month through FormBlends).

The compounded semaglutide alternative for excluded patients

For the majority of patients who cannot use the Wegovy Savings Card (government insurance holders, uninsured patients, those whose plans exclude Wegovy, or high-deductible patients early in the year), compounded semaglutide offers predictable monthly pricing without insurance involvement.

Pricing comparison (monthly):

Option	Cost range	Insurance required?	Eligibility restrictions
Wegovy with savings card	$25 to $275+	Yes	Commercial only, no government plans
Wegovy without savings card	$250 to $1,600	Optional	None, but cost prohibitive
Wegovy via PAP	$0	No	Income below 400% FPL
Compounded semaglutide (FormBlends)	$179 to $279	No	Medical eligibility (BMI, health screen)
Compounded semaglutide (other telehealth)	$199 to $499	No	Varies by platform

Key differences between Wegovy and compounded semaglutide:

Compounded semaglutide is not FDA-approved. It's prepared by a state-licensed 503A or 503B compounding pharmacy in response to an individual prescription. The active ingredient (semaglutide) is the same molecule, but the formulation, delivery method, and quality oversight differ.

Wegovy comes in a pre-filled, single-dose pen. Compounded semaglutide typically comes in a multi-dose vial that patients draw from using insulin syringes.

When compounded semaglutide makes sense:

• You're on Medicare, Medicaid, or TRICARE and can't use the savings card
• Your commercial insurance doesn't cover Wegovy
• Your deductible is high and you're early in the year
• You want predictable monthly costs without insurance paperwork
• Your income exceeds PAP limits but Wegovy's cost is still unaffordable

When brand-name Wegovy makes sense:

• Your copay with the savings card is under $100 per month
• You qualify for the PAP and can get Wegovy free
• You strongly prefer FDA-approved medications
• You want the convenience of a pre-filled pen

The decision is patient-specific. A licensed provider should review your insurance situation, income, preferences, and clinical factors before recommending either option. FormBlends providers conduct this assessment during the initial telehealth visit.

How to verify your specific savings in under 10 minutes

Step 1: Check your insurance formulary (3 minutes). Log into your insurance member portal. Navigate to the prescription drug list or formulary search tool. Search for "Wegovy" or "semaglutide 2.4 mg." Note which tier it's on and whether prior authorization is required.

If Wegovy isn't listed, the savings card won't work. Stop here and consider PAP or compounded alternatives.

Step 2: Call your pharmacy for a test claim (5 minutes). Call the pharmacy where you plan to fill the prescription. Provide your insurance information and ask them to run a test claim for Wegovy. This is a free service. The pharmacist will tell you the exact copay your insurance would charge.

Step 3: Calculate your savings card benefit (1 minute). If your copay is $250 or less, subtract $225. You'll pay $25. If your copay is above $250, subtract $225 from the copay. That's what you'll pay.

Step 4: Compare against alternatives (1 minute). If your final cost is above $150 per month, compare against compounded semaglutide ($179 to $279). If you're income-qualified, compare against the PAP ($0).

This verification prevents the most common surprise: arriving at the pharmacy expecting to pay $25 and learning your actual cost is $180 because your plan has high coinsurance.

The FormBlends clinical pattern: what we see in savings card eligibility

Across approximately 2,400 weight management consultations in Q1 2026, FormBlends providers documented insurance and savings card eligibility as part of the initial assessment. The pattern that emerged contradicts the common assumption that "most people with insurance can get Wegovy for $25."

Observed eligibility breakdown:

• 31% had commercial insurance with Wegovy coverage and copays at or below $250 (savings card brings cost to $25)
• 27% had commercial insurance with Wegovy coverage but copays or coinsurance above $250 (savings card helps but doesn't reach $25)
• 18% had commercial insurance that excluded Wegovy from the formulary entirely (savings card doesn't apply)
• 16% had Medicare or Medicare Advantage (federally prohibited from savings card)
• 8% had no insurance or were in high-deductible plans early in the year (savings card provides minimal benefit)

The clinical takeaway: only about one-third of patients presenting for weight management can access the "$25 per month" Wegovy pricing advertised in direct-to-consumer marketing. The remaining two-thirds face either higher costs with the card, no card eligibility, or need alternative pathways (PAP or compounded).

This pattern holds across geographic regions and age groups, though Medicare prevalence increases the percentage of ineligible patients in populations over age 65.

The implication for treatment planning: providers should screen for savings card eligibility early in the consultation and present compounded semaglutide as a primary option, not a fallback, for the 69% of patients who won't reach $25 monthly Wegovy costs.

FAQ

How much does the Wegovy manufacturer coupon save? The Wegovy Savings Card provides up to $225 in savings per monthly fill. If your insurance copay is $250, the card reduces it to $25. If your copay is $400, the card reduces it to $175. The maximum benefit is $225 per fill, with a limit of 13 fills per year.

Can I use the Wegovy savings card if I have Medicare? No. Federal law (Anti-Kickback Statute, 42 U.S.C. § 1320a-7b(b)) prohibits Medicare and Medicare Advantage patients from using manufacturer copay cards for any prescription medication. This applies to all Part D plans and Medicare Advantage plans, regardless of income.

Does the Wegovy coupon work without insurance? No. The Wegovy Savings Card requires active commercial insurance coverage for Wegovy. It reduces the copay after insurance processes the claim. If you don't have insurance or your insurance doesn't cover Wegovy, the card will not work. Uninsured patients should explore the Patient Assistance Program or compounded semaglutide.

Can I use the Wegovy savings card with Medicaid? No. Medicaid patients are prohibited from using manufacturer copay cards under the Medicaid Drug Rebate Program (42 U.S.C. § 1396r-8). This includes all state Medicaid programs, Medicaid managed care plans, and dual-eligible (Medicare-Medicaid) patients. Low-income Medicaid patients may qualify for the Novo Nordisk Patient Assistance Program instead.

How do I get the Wegovy manufacturer coupon? Download the Wegovy Savings Card from Wegovy.com or request a physical card by calling Novo Nordisk at 1-800-727-6500. Your prescribing provider may also have cards available in the office. No registration or activation is required. Present the card alongside your insurance card at the pharmacy.

What is the income limit for the Wegovy savings card? There is no income limit for the Wegovy Savings Card. Eligibility is based on insurance type (commercial vs government), not income. The separate Patient Assistance Program has an income limit of 400% federal poverty level ($60,240 for individuals, $124,800 for a family of four in 2026).

Does the Wegovy coupon work at all pharmacies? Yes. The Wegovy Savings Card works at all U.S. retail and mail-order pharmacies that accept commercial insurance, including CVS, Walgreens, Walmart, Costco, and independent pharmacies. It does not work at VA or Indian Health Service pharmacies.

Can I use GoodRx instead of the Wegovy savings card? GoodRx and similar discount cards provide cash prices, typically $1,100 to $1,300 for Wegovy. The Wegovy Savings Card works with insurance and can reduce costs to as low as $25. If you have commercial insurance that covers Wegovy, the savings card will almost always result in a lower cost than GoodRx. You cannot use both simultaneously.

How long does the Wegovy savings card last? The card is valid for 13 fills in a calendar year or 24 consecutive months of use, whichever comes first. After reaching the limit, the card deactivates and you pay your full insurance copay. There is no renewal or reapplication process for a new card after the limit expires.

What if my pharmacy says the Wegovy savings card didn't work? Common reasons the card fails: your insurance doesn't cover Wegovy, you have government insurance (Medicare/Medicaid), the pharmacist entered the card as primary instead of secondary, or you've exceeded the 13-fill limit. Ask the pharmacist to verify your insurance processed first and the savings card was applied as a secondary payer. If the card still fails, call Novo Nordisk support at 1-800-727-6500.

Is there a Wegovy savings card for Medicare patients? No. Federal law prohibits manufacturer copay assistance for Medicare patients. Medicare patients who cannot afford Wegovy should apply for the Novo Nordisk Patient Assistance Program if household income is below 400% federal poverty level, or consider compounded semaglutide as an alternative.

Can I use the Wegovy coupon if my insurance denied coverage? No. The savings card requires active insurance coverage. If your insurance denied the Wegovy claim, there's no copay for the card to reduce. You should appeal the denial, apply for a formulary exception, or explore the Patient Assistance Program or compounded semaglutide while the appeal processes.

Sources

1. Novo Nordisk. Wegovy Prescribing Information. 2024.
2. Novo Nordisk. Annual Report 2025.
3. Novo Nordisk. Investor Presentation Q4 2025.
4. Centers for Medicare & Medicaid Services. Medicare Enrollment Dashboard. 2026.
5. U.S. Department of Health and Human Services. Federal Poverty Guidelines. 2026.
6. 42 U.S.C. § 1320a-7b(b). Social Security Act, Anti-Kickback Statute.
7. 42 U.S.C. § 1396r-8. Medicaid Drug Rebate Program.
8. 10 U.S.C. § 1074g. TRICARE Pharmacy Benefits Program.
9. 38 U.S.C. § 8126. Prohibition on Pharmaceutical Manufacturer Payments to VA.
10. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021.
11. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
12. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022.
13. Kadowaki T et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2022.
14. FormBlends internal clinical data. Q1 2026 patient insurance and eligibility patterns. N=2,400.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Saxenda, and Rybelsus are registered trademarks of Novo Nordisk A/S. Medicare, Medicaid, and TRICARE are registered trademarks of the U.S. Department of Health and Human Services and Department of Defense. GoodRx is a registered trademark of GoodRx Holdings, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.